Novartis statement on the conclusion of the hearing regarding the Glivec patent before the Supreme Court of India

Novartis statement on the conclusion of the hearing regarding the Glivec patent before the Supreme Court of India


The hearing of the special leave petition filed by Novartis before the Supreme Court of India regarding the "Glivec patent" concluded on Tuesday, 4 December 2012.

Novartis deeply appreciates the opportunity to present the case before the Court and will look forward to the outcome. Novartis pursued the litigation with a view to seek clarity on the unique aspects of India's patent law and to foster an innovative environment to the benefit of patients.

The verdict and the timing of its ruling are entirely at the discretion of the court. We expect to have a decision sometime before the end of Q1 of 2013.

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.